Literature DB >> 17131321

Up-regulation of Mac-2 binding protein by hTERT in gastric cancer.

Yuk Pheel Park1, Seung-Chul Choi, Joo Heon Kim, Eun Young Song, Jae Wha Kim, Do-Young Yoon, Young Il Yeom, Jong-Seok Lim, Jong Wan Kim, Sang-Gi Paik, Hee Gu Lee.   

Abstract

Mac-2 binding protein (Mac-2BP) is a secreted tumor antigen that is elevated in many cancers and implicated in tumor metastasis, as well as cell adhesion and immune functions. We focused on the human telomerase reverse transcriptase (hTERT) induced Mac-2BP expression and the relationship between Mac-2BP expression and the progression of gastric cancer. A cDNA expression array analysis was performed on the telomerase-negative cell line, SW13, which was engineered to overexpress hTERT when compared with the parental SW13 cell. hTERT-induced Mac-2BP expression was confirmed via RT-PCR and Northern blotting. ELISA and flow cytometric analyses revealed that Mac-2BP protein was increased by 2- to 4-fold in hTERT-overexpressing cells compared with the mock control. Mac-2BP expression was significantly reduced when the overexpressed hTERT was neutralized by the introduction of hTERT-specific siRNA. These results suggest that Mac-2BP expression is modulated by hTERT. Mac-2BP levels in both gastric cancer cells and tumor tissues were determined via Northern blot analysis and immunohistochemistry. Mac-2BP protein was highly expressed in most gastric cancer cell lines, and gastric tumor tissues were stained more densely than normal tissues. The intracellular and secreted Mac-2BP levels were also evaluated via ELISA, indicating that Mac-2BP was expressed and secreted more abundantly in gastric cancer patients than in healthy donors. The elevated serum Mac-2BP level in gastric tumor patients was also significantly associated with distant metastasis (p = 0.05) and higher tumor stage (p = 0.04). Our findings suggest that Mac-2BP is induced by hTERT, and that it may prove to be a useful prognostic marker for the detection of malignant progression of metastatic stomach cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17131321     DOI: 10.1002/ijc.22369

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Prevalidation of salivary biomarkers for oral cancer detection.

Authors:  David Elashoff; Hui Zhou; Jean Reiss; Jianghua Wang; Hua Xiao; Bradley Henson; Shen Hu; Martha Arellano; Uttam Sinha; Anh Le; Diana Messadi; Marilene Wang; Vishad Nabili; Mark Lingen; Darly Morris; Timothy Randolph; Ziding Feng; David Akin; Dragana A Kastratovic; David Chia; Elliot Abemayor; David T W Wong
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-01       Impact factor: 4.254

2.  Analysis of the human pancreatic stellate cell secreted proteome.

Authors:  Angela Y Wehr; Emma E Furth; Vineet Sangar; Ian A Blair; Kenneth H Yu
Journal:  Pancreas       Date:  2011-05       Impact factor: 3.327

3.  A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma.

Authors:  Ayaka M Silverman; Rie Nakata; Hiroyuki Shimada; Richard Sposto; Yves A DeClerck
Journal:  Cancer Res       Date:  2012-03-02       Impact factor: 12.701

4.  SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome.

Authors:  Manoj Kumar Kashyap; H C Harsha; Santosh Renuse; Harsh Pawar; Nandini A Sahasrabuddhe; Min-Sik Kim; Arivusudar Marimuthu; Shivakumar Keerthikumar; Babylakshmi Muthusamy; Kumaran Kandasamy; Yashwanth Subbannayya; Thottethodi Subrahmanya Keshava Prasad; Riaz Mahmood; Raghothama Chaerkady; Stephen J Meltzer; Rekha V Kumar; Anil K Rustgi; Akhilesh Pandey
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

5.  SILAC-based quantitative proteomic analysis of gastric cancer secretome.

Authors:  Arivusudar Marimuthu; Yashwanth Subbannayya; Nandini A Sahasrabuddhe; Lavanya Balakrishnan; Nazia Syed; Nirujogi Raja Sekhar; Teesta V Katte; Sneha M Pinto; Srinivas M Srikanth; Praveen Kumar; Harsh Pawar; Manoj K Kashyap; Jagadeesha Maharudraiah; Hassan Ashktorab; Duane T Smoot; Girija Ramaswamy; Rekha V Kumar; Yulan Cheng; Stephen J Meltzer; Juan Carlos Roa; Raghothama Chaerkady; T S Keshava Prasad; H C Harsha; Aditi Chatterjee; Akhilesh Pandey
Journal:  Proteomics Clin Appl       Date:  2013-05-21       Impact factor: 3.494

6.  Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.

Authors:  Heinz Läubli; Frederico Alisson-Silva; Michal A Stanczak; Shoib S Siddiqui; Liwen Deng; Andrea Verhagen; Nissi Varki; Ajit Varki
Journal:  J Biol Chem       Date:  2014-10-15       Impact factor: 5.157

7.  Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes.

Authors:  Rajaventhan Srirajaskanthan; Martyn E Caplin; Mark G Waugh; Jennifer Watkins; Tim Meyer; J Justin Hsuan; Nicholas J Beaumont
Journal:  Mol Cell Proteomics       Date:  2009-12-17       Impact factor: 5.911

8.  Salivary proteomics for oral cancer biomarker discovery.

Authors:  Shen Hu; Martha Arellano; Pinmanee Boontheung; Jianghua Wang; Hui Zhou; Jiang Jiang; David Elashoff; Roger Wei; Joseph A Loo; David T Wong
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

9.  Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.

Authors:  Ji Hee Lee; Myong-Suk Park; Jun-Eul Hwang; Sang-Hee Cho; Woo-Kyun Bae; Hyun-Jeong Shim; Dae-Eun Kim; Ik-Joo Chung
Journal:  Cell Mol Immunol       Date:  2013-03-25       Impact factor: 11.530

10.  Cyclophilin C-associated protein (CyCAP) knock-out mice spontaneously develop colonic mucosal hyperplasia and exaggerated tumorigenesis after treatment with carcinogen azoxymethane.

Authors:  Emina Emilia Torlakovic; Vicki Keeler; Chang Wang; Hyun J Lim; Leslie Ann Lining; Suzanne Laferté
Journal:  BMC Cancer       Date:  2009-07-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.